A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53

(2020) Nitin Jain et al.   BLOOD

ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

(2020) Jeff P. Sharman et al.   BLOOD

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

(2020) Kirsten Fischer et al.   BLOOD

Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

(2020) Matthew S. Davids et al.   CLINICAL CANCER RESEARCH

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

(2020) Jeff P Sharman et al.   LANCET

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

(2019) Tait D. Shanafelt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

(2019) Kirsten Fischer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial

(2019) Anne-Sophie Michallet et al.   Lancet Haematology

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial

(2019) Matthew S Davids et al.   Lancet Haematology

Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia

(2019) Ian W. Flinn et al.   AMERICAN JOURNAL OF HEMATOLOGY

Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a Phase 1 study

(2018) Susan O'Brien et al.   AMERICAN JOURNAL OF HEMATOLOGY

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

(2018) Ian W. Flinn et al.   BLOOD

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity

(2016) B. L. Lampson et al.   BLOOD

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group

(2016) Gabor Kovacs et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

(2016) Barbara Eichhorst et al.   LANCET ONCOLOGY

Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia

(2015) D. Rossi et al.   BLOOD

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

(2015) P. A. Thompson et al.   BLOOD

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

(2015) K. Fischer et al.   BLOOD

Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL

(2014) P. Strati et al.   BLOOD

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

(2012) Sebastian Böttcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD